Bausch Health Q2 Earnings Beat Estimates, Raises 2026 Outlook

Earnings

โดย Zacks Investment Research·Read original

Summary · why it matters

Bausch Health Companies reported second-quarter 2026 adjusted earnings of $1.26 per share, beating the Zacks Consensus Estimate of 96 cents and rising 40% year over year. Revenues increased 13% to $2.85 billion, surpassing the consensus of $2.65 billion, driven by growth in Salix, Solta Medical, and Bausch + Lomb. Salix revenues climbed 21% to $758 million, with Xifaxan up 26% to $664 million, while Solta Medical surged 38% to $176 million. The company raised its full-year 2026 consolidated revenue guidance to a range of $10.79 billion to $11.04 billion, up from the prior $10.67 billion to $10.92 billion, and lifted its adjusted EBITDA forecast to between $4.05 billion and $4.18 billion.